Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in London, BM. The stock last traded at $0.96, down 4.92% on the session, giving a market capitalisation of $61.1M. On trailing twelve-month figures it carries a trailing P/E of -4.16, a net margin of 0.0%. Its beta of 0.46 implies it has historically moved less than the broad market.
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Tiziana Life Sciences Ltd is most often compared with the following Healthcare names: